A UK regulator, Medicines and Healthcare products Regulatory Agency (MHRA), has received nearly 400 reports of serious pancreas trouble from users of GLP-1s, New York Post reported
But the FDA has not currently changed the prescribing guidelines for these drugs to exclude people with depression
Liraglutide 1.8 mg and semaglutide 2.4 mg are established GLP1-RAs for obesity treatment
We offer personalized consultations to assess your health needs and create a tailored treatment plan
And so we started him on it and it, it, its been a game changer, a game changer, so much so that I started to look at all the research, you know, and youve been really great at supplying so much of this research and thats the crazy thing, theres so much research about this
Published 2019 Oct 10